British regulators claim that GlaxoSmithKline paid generic drug makers to delay the inroduction of generic versions of its Seroxat drug to the U.K. market. More
-
-
Sponsored By:
-
Sponsored By:
GSK
Recent Articles
35 Actions to Take on Monday’s Market Dip
Gold plunges to a two-year low, Brent crude falls to $100 a barrel, commodity prices and the markets retreat. Here is how to play these 35 stocks on the news More
An HIV ‘Cure’? Let’s Not Overstate the Success
Merck, J&J and others won't be dropping their research to recreate the success seen in the early treatment of an HIV-positive child. More
Newborn Cured of HIV
A little girl in Mississippi, who was born infected with HIV, was apparently cured of the disease after receiving a three drug cocktail shortly after birth. More
Biotech Movers: Arena Gets Warned, MAP Gets an Offer
Among last week's highlights, Europe raises questions about Arena's obesity drug, Belviq, and Allergan offers $958 million for MAP Pharmaceuticals. More
3 Pharmaceutical Stocks to Sell Now
The ratings of three Pharmaceutical stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell"). More
Flu’s Pain Is All Gain for These Companies
As this year's flu season intensifies, so do the profits for some businesses such as vaccine makers, pharmacies and even certain food and beverage makers. More
